HGT 1110: Phase I/II started

Shire disclosed in its 3Q12 earnings that it began the open-label, dose-escalation, European Phase I/II IDEAMLD trial to evaluate 10, 30 and 100 mg intrathecal HGT 1110 every other week for 38 weeks i...